[Use of autologous blood mononuclear cells in the complex treatment of corneal ulcers].
A new method was developed to treat corneal ulcers with instillations of autologous blood mononuclear cells during traditional pharmacotherapy. Clinical trials showed a significantly more arrest of an exudative-destructive reaction: the time of ulcerative defect debridement from necrotic masses reduced by 1.5-2 times, resolution of a perifocal edema and infiltration by 1.6 times. There was simultaneously an acceleration of transition of inflammation to a phase of reparation with the formation of corneal opacity of less intensity and dimension. Instillations of autologous blood mononuclear cells showed a 4.4-fold reduction in the total number of complications as compared with the controls.
Zapuskalov
I V
IV
Krivosheina
O I
OI
Elegesheva
O N
ON
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003320:Corneal Ulcer / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery / Q000628:therapy* / Q000821:virology; D003627:Data Interpretation, Statistical; D003646:Debridement; D005260:Female; D006801:Humans; D008297:Male; D009000:Monocytes / Q000637:transplantation*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000998:Antiviral Agents